These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29851534)

  • 1. Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it.
    Faraji F; Karjoo Z; Moghaddam MV; Heidari S; Emameh RZ; Falak R
    Int Rev Immunol; 2018; 37(6):301-315. PubMed ID: 29851534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of immunogenicity for therapeutic proteins: state of the art.
    De Groot AS; Moise L
    Curr Opin Drug Discov Devel; 2007 May; 10(3):332-40. PubMed ID: 17554860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.
    Koren E; De Groot AS; Jawa V; Beck KD; Boone T; Rivera D; Li L; Mytych D; Koscec M; Weeraratne D; Swanson S; Martin W
    Clin Immunol; 2007 Jul; 124(1):26-32. PubMed ID: 17490912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to prediction of immune responses to therapeutic proteins during preclinical development.
    Perry LC; Jones TD; Baker MP
    Drugs R D; 2008; 9(6):385-96. PubMed ID: 18989990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of immunogenicity of therapeutic proteins: validity of computational tools.
    Bryson CJ; Jones TD; Baker MP
    BioDrugs; 2010 Feb; 24(1):1-8. PubMed ID: 20055528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
    Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
    Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.
    Koren E; Zuckerman LA; Mire-Sluis AR
    Curr Pharm Biotechnol; 2002 Dec; 3(4):349-60. PubMed ID: 12463417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell epitope: friend or foe? Immunogenicity of biologics in context.
    Weber CA; Mehta PJ; Ardito M; Moise L; Martin B; De Groot AS
    Adv Drug Deliv Rev; 2009 Sep; 61(11):965-76. PubMed ID: 19619593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy.
    Mufarrege EF; Giorgetti S; Etcheverrigaray M; Terry F; Martin W; De Groot AS
    Clin Immunol; 2017 Mar; 176():31-41. PubMed ID: 28089609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.
    De Groot AS; McMurry J; Moise L
    Curr Opin Pharmacol; 2008 Oct; 8(5):620-6. PubMed ID: 18775515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of different recombinant rabbit hemorrhagic disease virus-like particles carrying CD8+ T cell epitope from chicken ovalbumin (OVA).
    Chen M; Song Y; Fan Z; Jiang P; Hu B; Xue J; Wei H; Wang F
    Virus Res; 2014 Apr; 183():15-22. PubMed ID: 24457072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of therapeutic proteins: clinical implications and future prospects.
    Schellekens H
    Clin Ther; 2002 Nov; 24(11):1720-40; discussion 1719. PubMed ID: 12501870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.
    Choi Y; Verma D; Griswold KE; Bailey-Kellogg C
    Methods Mol Biol; 2017; 1529():375-398. PubMed ID: 27914063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.
    Bugelski PJ; Treacy G
    Curr Opin Mol Ther; 2004 Feb; 6(1):10-6. PubMed ID: 15011776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV.
    Brinck-Jensen NS; Vorup-Jensen T; Leutscher PD; Erikstrup C; Petersen E
    BMC Immunol; 2015 Nov; 16():65. PubMed ID: 26526193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method.
    Gutiérrez AH; Martin WD; Bailey-Kellogg C; Terry F; Moise L; De Groot AS
    BMC Bioinformatics; 2015 Sep; 16():290. PubMed ID: 26370412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of biopharmaceuticals in laboratory animals.
    Wierda D; Smith HW; Zwickl CM
    Toxicology; 2001 Feb; 158(1-2):71-4. PubMed ID: 11164995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.